| Market Capitalization (Millions $) |
32,351 |
| Shares
Outstanding (Millions) |
128 |
| Employees |
2,100 |
| Revenues (TTM) (Millions $) |
2,248 |
| Net Income (TTM) (Millions $) |
-278 |
| Cash Flow (TTM) (Millions $) |
154 |
| Capital Exp. (TTM) (Millions $) |
34 |
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc. is a biotechnology company that specializes in the development of RNA interference (RNAi) therapeutics. RNAi is a natural cellular process that controls the expression of genes, and Alnylam's approach is to use this process to treat various diseases. The company's platform allows for the specific silencing of disease-causing genes, preventing them from producing proteins that cause harm.
Alnylam was founded in 2002 and is based in Cambridge, MA. The company has a strong pipeline of RNAi therapeutic programs, with a focus on genetic diseases, liver diseases, and central nervous system (CNS) disorders. Its lead program is Givlaari (givosiran), a treatment for acute hepatic porphyria (AHP), a rare and life-threatening genetic disease.
Alnylam's pipeline also includes a treatment for hemophilia A and B, a rare genetic bleeding disorder, and a treatment for ATTR amyloidosis, a condition that causes a buildup of abnormal proteins in the body's organs and tissues. The company has several other preclinical and clinical programs in development for a broad range of diseases.
Alnylam has partnered with several pharmaceutical companies, including Sanofi and Regeneron, to develop RNAi therapeutics. The company has also established collaborations with academic institutions and research organizations to advance its platform and expand its pipeline.
Alnylam has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has reported positive financial results in recent quarters, with revenue increasing year over year. Alnylam also received approval for its first RNAi therapeutic, Onpattro (patisiran), in 2018, marking a significant milestone in the company's history.
Overall, Alnylam Pharmaceuticals Inc. is a leading biotechnology company in the RNAi therapeutics space, with a strong pipeline and a focus on developing treatments for rare diseases. The company's innovative approach to gene silencing has the potential to offer significant benefits to patients with a range of conditions.
Company Address: 675 West Kendall Street Cambridge 2142 MA
Company Phone Number: 551-8200 Stock Exchange / Ticker: NASDAQ ALNY
|
3.11% 